In the last trading session, 1.24 million shares of the Regenxbio Inc (NASDAQ:RGNX) were traded, and its beta was 1.21. Most recently the company’s share price was $6.33, and it changed around $0.44 or 7.47% from the last close, which brings the market valuation of the company to $317.26M. RGNX currently trades at a discount to its 52-week high of $19.38, offering almost -206.16% off that amount. The share price’s 52-week low was $5.03, which indicates that the current value has risen by an impressive 20.54% since then. We note from Regenxbio Inc’s average daily trading volume that its 10-day average is 1.2 million shares, with the 3-month average coming to 987.22K.
Regenxbio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.38. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 1 recommended RGNX as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Regenxbio Inc is expected to report earnings per share of 0.34 for the current quarter.
Regenxbio Inc (NASDAQ:RGNX) trade information
Instantly RGNX has showed a green trend with a performance of 7.47% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 6.36 on recent trading dayincreased the stock’s daily price by 0.47%. The company’s shares are currently down -18.11% year-to-date, but still up 6.75% over the last five days. On the other hand, Regenxbio Inc (NASDAQ:RGNX) is -5.80% down in the 30-day period. We can see from the shorts that 5.22 million shares have been sold at a short interest cover period of 4.97 day(s).
The consensus price target as assigned by Wall Street analysts is $24, which translates to bulls needing to increase their stock price by 73.62% from its current value. Analyst projections state that RGNX is forecast to be at a low of $22 and a high of $30.
Regenxbio Inc (RGNX) estimates and forecasts
The year-over-year growth rate is expected to be 290.36%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 105.35M in revenue for the current quarter. 9 analysts expect Regenxbio Inc to make 35.7M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 15.62M and 22.3M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 574.37%. Forecasts for the next quarter put sales growth at 60.14%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.18%. Regenxbio Inc earnings are expected to increase by 83.78% in 2025, but the outlook is positive 28.31% per year for the next five years.
RGNX Dividends
Regenxbio Inc’s next quarterly earnings report is expected to be released on 2025-Mar-12.
Regenxbio Inc (NASDAQ:RGNX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 7.60% of Regenxbio Inc shares, and 87.43% of them are in the hands of institutional investors. The stock currently has a share float of 94.62%. Regenxbio Inc stock is held by 252.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 17.0142% of the shares, which is about 8.61 million shares worth $100.73 million.
VANGUARD GROUP INC, with 11.1818% or 5.11 million shares worth $59.83 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
JPMorgan Trust II-JPMorgan Small Cap Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.99 shares worth $12.6 million, making up 3.97% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.4 shares worth around $8.86 million, which represents about 2.79% of the total shares outstanding.
